Physician profile
Eunji Kwon
NPI 1124401401
$1,566.24
in general payments reported to CMS, 2019-2025
15 companies · $254 in 2025
The $254 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.03 · 2020: $62.89 · 2021: $470 · 2022: $468 · 2023: $293 · 2025: $254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $546.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $436.20 | 2020-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $269.14 | 2020-2023 | Eliquis |
| Alexion Pharmaceuticals, INC. | $254.62 | 2021-2023 | Ultomiris |
| Mirum Pharmaceuticals, INC. | $137.82 | 2025 | Livmarli |
| Abbvie INC. | $108.59 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $75.08 | 2021-2023 | |
| Pfizer INC. | $55.82 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $44.53 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.05 | 2022-2025 | Jardiance |
| Exact Sciences Corporation | $37.48 | 2025 | Cologuard Collection Kit |
| Vapotherm INC | $31.42 | 2020 | |
| Gilead Sciences, INC. | $20.38 | 2021 | |
| Portola Pharmaceuticals, LLC | $19.03 | 2019 | |
| Novo Nordisk INC | $19.02 | 2025 | Rybelsus, Ozempic |
| Paratek Pharmaceuticals, INC. | $18.06 | 2023 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eunji Kwon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.